PDGFRA expression in K27M gliomasEmail Principal Investigator
High grade glioma is a rare and difficult to treat pediatric brain cancer. A specific subset of HGGs, those with the H3K27M mutation, currently have no treatment options available that have been shown to fully cure the disease. Researchers have garnered data that suggests the use of PDGFRA inhibitors could be used to treat HGGs. However, additional data suggests that the impact of such inhibitors differs between tumor subtypes, such as those with the H3K27M mutation. Researchers aim to understand these differences by analyzing data about the genome, or DNA, of these tumors as well as the transcriptome, the name used to describe genes expressed within tumors. Understanding this type of data could help researchers determine whether PDGFRA inhibitors will be applicable for use on HGG patients. This work requires a large dataset that CBTN is particularly suited to provide. Researchers aim to use this research to support the use of PDGFRA targeted therapy in H3K27M HGGs, increasing treatment options for patients and families.
What are the goals of this project?
Researchers aim to better understand HGGs with the H2K37M mutations so that they can assess PDGFRA inhibitors as treatment for this tumor.
What is the impact of this project?
This project could expand potential treatment options for patients with HGGs.
Why is the CBTN request important to this project?
The data available through CBTN includes specific information needed to assess these tumors in depth.
Harvard Medical School
Harvard Medical School is the graduate medical school of Harvard University and is located in the Longwood Medical Area of Boston, Massachusetts. Harvard Medical School has affiliation agreements with 15 of the world’s most prestigious hospitals and research institutes, vital partners that provide c